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Summary
Although most autoimmune diseases are considered to be CD4 T cell- or 
antibody-mediated, many respond to CD20-depleting antibodies that have 
limited influence on CD4 and plasma cells. This includes rituximab, ob-
linutuzumab and ofatumumab that are used in cancer, rheumatoid arthritis 
and off-label in a large number of other autoimmunities and ocrelizumab 
in multiple sclerosis. Recently, the COVID-19 pandemic created concerns 
about immunosuppression in autoimmunity, leading to cessation or a delay 
in immunotherapy treatments. However, based on the known and emerg-
ing biology of autoimmunity and COVID-19, it was hypothesised that 
while B cell depletion should not necessarily expose people to severe SARS-
CoV-2-related issues, it may inhibit protective immunity following infection 
and vaccination. As such, drug-induced B cell subset inhibition, that controls 
at least some autoimmunities, would not influence innate and CD8 T cell 
responses, which are central to SARS-CoV-2 elimination, nor the hyper-
coagulation and innate inflammation causing severe morbidity. This is 
supported clinically, as the majority of SARS-CoV-2-infected, CD20- 
depleted people with autoimmunity have recovered. However, protective 
neutralizing antibody and vaccination responses are predicted to be blunted 
until naive B cells repopulate, based on B cell repopulation kinetics and 
vaccination responses, from published rituximab and unpublished ocreli-
zumab (NCT00676715, NCT02545868) trial data, shown here. This suggests 
that it may be possible to undertake dose interruption to maintain inflam-
matory disease control, while allowing effective vaccination against SARS-
CoV-29, if and when an effective vaccine is available.
Keywords: autoimmunity, B cell, CD20, COVID-19, immunotherapy, multiple 
sclerosis, ocrelizumab, rheumatoid arthritis, rituximab
Introduction
Although many people consider CD4 T helper type 17 
(Th17) cells to be central effectors in autoimmunity, 
response to therapy has indicated that B cell-depleting 
drugs exhibit high efficacy in autoimmune and neuroim-
munological diseases [1–3]. As such, not only are CD20-
depleting agents approved for B cell-related cancers, but 
they are increasingly being used on- and off-label in 
autoimmune diseases [1,4]. Ocrelizumab has recently been 
licensed for the treatment of multiple sclerosis (MS), and 
antibodies including ofatumumab and ublituximab are in 
development for MS [5–7]. In addition, rituximab, which 
is approved for rheumatoid arthritis (RA) and pemphigus 
vulgaris, is frequently used off-label in MS, neuromyelitis 
optica spectrum disorders (NMOSD) and a variety of 
other autoimmunities [1,3,5,8]. Such off-label use provides 
valuable insight into the biology of CD20-depleting therapy 
[3]. For this reason, cells within the memory B cell subsets 
appear to be important targets for disease control, and 
their depletion and slow repopulation may, in part, account 
for the long-term disease control seen from short-term 
treatment cycles with alemtuzumab, cladribine, ocrelizumab 
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and rituximab [2,3,9,10]. Using rituximab to deplete repopu-
lating memory B cells when they reach predefined levels 
can maintain clinical remission while reducing the fre-
quency of infusions in RA, NMO, MS and other conditions 
[3,11–13]. Translating this knowledge may help to improve 
the benefit  :  risk balance of ocrelizumab [9]. This is cur-
rently highly relevant, as repeated 6-monthly CD20 deple-
tion is associated with immunoglobulin (Ig)M and then 
IgA and IgG hypogammaglobulinaemia in some individuals, 
and also a small but increased risk of severe infections 
[14–16].
Immunological issues of COVID-19
The severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) causing coronavirus disease 2019 (COVID-19) 
has killed hundreds of thousands of humans in a global 
pandemic [17]. Severe COVID-19 is often associated with 
lymphopenia [18], initially causing great concern over the 
use of immunosuppressive agents. In some cases, this led 
to the cessation or delay of treatment of autoimmunity 
[19,20]. However, it is increasingly evident that lympho-
penia is a consequence rather than a cause of infection 
[20,21]. While the immune system eliminates SARS-CoV-2 
in most individuals (Fig. 1), viral escape, immune exhaus-
tion and elevated cytokine release can lead to hyperactiva-
tion of the innate immune response, vascular damage and 
hypercoagulation (Fig. 1), which can lead to significant 
morbidity, acute respiratory distress, multi-organ failure 
and, in some cases, death [17,18,22]. While immunotherapy 
may have some value in treating severe COVID-19 [23], 
the development of a SARS-CoV-2 vaccine is considered 
to be important for protecting the uninfected [24]. A vac-
cination programme should help to create herd immunity 
against the COVID-19 virus [25]. Therefore, not only is 
it relevant to determine how disease-modifying treatments 
(DMT) influence susceptibility to infection and length of 
the carrier state, it is also important to consider how 
DMT may influence immunity to reinfection and potential 
vaccine responses [20].
Surprisingly, there are limited published data concerning 
the influence of ocrelizumab on immune subsets, vaccine 
responses, durability of response and the safety of extend-
ing infusion intervals. This prompted us to report data 
available within the public domain that addressed some 
of these safety concerns [9]. These data indicate that delay-
ing ocrelizumab [9] and rituximab [10,26] re-infusion should 
be associated with minor risk of disease reactivation, based 
on B cell subset depletion and repopulation kinetics [9].
CD20-B cell-depleting agents do not markedly expose 
people to life-threatening COVID-19
Based on previous understanding of the immune response 
to SARS-CoV and SARS-CoV-2, animal studies of the 
elimination of coronaviruses, informative COVID-19 case 
reports and preliminary reports of COVID-19 pathology 
[20,27–29], the biology of MS, MS treatments and 
COVID-19 have suggested that halting treatment may 
cause more harm than good through ineffective disease 
control [20,30]. This indicates that a more pragmatic 
approach, supported by others in the field of MS and 
other conditions, may be of value [9,31,32]. It appears 
that the innate immune response, and perhaps later 
anti-viral CD8 T cell responses, could eliminate the 
SARS-CoV2 before significant antibody responses have 
developed [20,28,33] (Fig. 1), suggesting that most MS 
treatments that largely exhibit limited persistent effects 
on the innate immune and CD8 T cell responses would 
have limited influence on COVID-19. SARS-CoV-2 is 
eliminated by the majority of people with MS and other 
autoimmunities on immunotherapies, without significant 
consequences [34–56] (Table 1). Anti-viral antibodies, 
notably those targeting the receptor binding domain of 
the viral spike protein, clearly neutralize the virus [57,58] 
and can contribute to the elimination of the primary 
SARS-CoV-2 infection in humans [58,59]. However, B 
cells do not appear to be an absolute requirement for 
recovery. This is shown by the recovery of people geneti-
cally lacking B cells, such as with X-linked hypogam-
maglobulinaemia [60,61], and is reinforced by the finding 
that the vast majority of people treated with CD20 B 
cell-depleting agents in MS recover from COVID-19 
[37–56] (Table 1). Furthermore, B cell depletion is unlikely 
to influence, or be significantly influenced by, the vas-
cular pathology and hypercoagulopathy that are major 
pathological features in COVID-19 that contribute to 
the acute respiratory distress syndrome, cardiovascular, 
cerebrovascular and other non-pulmonary morbidities 
[9,20,22,62,63] (Fig. 1). Importantly, it provides another 
rationale as to why immunosuppressive treatments in 
MS and other autoimmunities [44,64,65] have not notice-
ably influenced COVID-19 susceptibility and prognosis. 
People with MS appear to respond to SARS-CoV-2 in 
a similar way to the general population, where severe 
disease is notably influenced by age and comorbidities, 
such as diabetes and obesity [18,43,44,66]. While this 
information is further consolidated by biology and the 
clinical evidence (Table 1), it may focus attention away 
from issues of being infected with SARS-CoV-2 [20] to 
methods of avoiding SARS-CoV-2 infection in uninfected 
individuals, as discussed below.
Ocrelizumab is the only DMT that is licenced across 
the spectrum of primary progressive and relapsing MS 
[5]. In comparison to other high-efficacy DMT used in 
MS it has limited monitoring requirements, fewer restric-
tions on usage compared to cladribine and alemtuzumab 
and off-label alternatives are widely used, and pharma-
covigilance reports have been released [8,40,67]. Therefore, 
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it is perhaps not surprising that there is currently more 
information about the influence of CD20 depletion and 
COVID-19 disease outcome than for other high-efficacy 
DMT in MS [49,44] (Table 1). This is consistent with, 
albeit limited, information in people with rheumatic 
diseases [66,68] indicating that people generally recover, 
while the few reported deaths may be linked to co-
morbidities [44]. The suggestion that rituximab treatment 
may increase risk of infection should be considered in 
the context of possible sampling biases, although this 
Fig. 1. Pathobiology of COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects cells in the lung and the gut via the 
angiotensin-converting enzyme 2 (ACE2). This blocks ACE2-induced formation of anti-oxidant angiotensin, facilitating oxygen free-radical formation 
and vascular damage. The innate immune response provides the initial line of defence against the virus, while a CD8 anti-viral T cell response and 
neutralizing and complement-fixing antibody response serve to remove the virus in the majority of people. However, the virus triggers suppression of 
interferon responses and other viral escape mechanisms that in a minority of people stimulate the innate immune response leading to lymphocyte 
apoptosis that blocks their regulatory signals and, in some cases, releases a cytokine storm that drives hyper-innate inflammation. This, in part, causes 
acute respiratory distress. Importantly, this augments vascular damage that accentuates the respiratory distress and leads to von Willebrand factor 
release into the blood. This contributes to the formation of microthrombi, contributing to respiratory distress and vascular embolism that may be fatal. 
Adapted from Henry et al. 2020 [22].
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could be supported by data reported in social media 
from Sweden [40,54] (Table 1). It is evident that both 
rituximab and ocrelizumab cause IgM hypogammaglob-
ulinaemia in some people within a few treatment cycles, 
and this and IgA and IgG hypogammaglobulinaemia 
increases with repeated infusions, potentially contributing 
to infection [9,14–16]. A delayed IgM response to SARS-
CoV-2, which usually appears a few days after symptom 
onset, may contribute to disease severity [69,70]. With 
time, CD20 depletion is also associated with reduced 
IgA responses [15], and similarly early IgA responses 
may also be important for efficient clearance of SARS-
CoV-2 [15,71,72]. However, as yet there is no compelling 
evidence that CD20 depletion increases the severity of 
COVID-19 compared to the general population [40,41], 
although in people with genetically dysfunctional B cells 
this has been suggested [62]. In addition, hypogamma-
globulinaemia may inhibit SARS-CoV-2 cross-reactive, 
protective antibodies generated from immunity from 
previous coronavirus infection, which has been shown 
at the T and B cell level [73,74], and seen previously 
with SARS and common cold-causing coronaviruses [75]. 
In contrast, it has been questioned whether benefit may 
be imparted [37,43], as B cell depletion could lead to 
limited antibody-mediated enhancement of macrophage 
activity and complement-mediated damage and antibody 
levels have been associated with severe COVID-19 
[71,76,77]. Although some people seroconvert and gener-
ate an anti-SARS-CoV-2 response, this is expected to 
be, and sometimes is, blunted or absent due to the 
inhibition of antibody responses by anti-CD20 B cell 
depletion [39,50–53]. The antibody titre required for 
protection against SARS-CoV-2 and the quality and the 
neutralizing potential of the antibody response after 
CD20 depletion are currently unknown [39,50–53]. 
However, even in non-immunosuppressed, notably asymp-
tomatic, cases that produce low-titre antibody responses, 
many people do not produce a marked or long-lasting 
neutralizing antibody response [78–80]. Perhaps benefit 
may be achieved by vaccination to boost immunity.
Table 1. Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in people treated with CD20-depleting antibodies in multiple 
sclerosis
CD20 antibody Total no. infected No. hospitalised No. in intensive care No. of deaths Reference
Ocrelizumab 1 1 0 0 [37]
Ocrelizumab 1 1 0 0 [38]
Ocrelizumab 2 0 0 0 [39]
Ocrelizumab 34 2 0 0 [40]
Ocrelizumab 100 26 5 n.r. [41]
Ocrelizumab 1 1 0 0 [42]
Ocrelizumab 1 0 0 0 [43]
Ocrelizumab 11 5 2 n.r. [44]
Ocrelizumab 26 n.r. 2 0 [45]
Ocrelizumab 59 n.r. n.r. 2 [46]
Ocrelizumab 10 n.r. n.r. n.r. [47]
Ocrelizumab 2 0 0 0 [48]
Ocrelizumab 38 10 3 0 [49]
Ocrelizumab 7 3 0 0 [50]
Ocrelizumab 1 1 0 0 [51]
Ocrelizumab 2 0 0 0 [52]
Ocrelizumab 1 0 0 0 [53]
Subtotal 297 50 12 2
Rituximab 7 1 0 0 [39]
Rituximab 21 ≤ 2 0 0 [40]
Rituximab 2 n.r. 1 1 [45]
Rituximab 9 n.r. n.r. 0 [46]
Rituximab 6 n.r. n.r. n.r. [47]
Rituximab 17 9 3 1 [49]
Rituximab 1 1 1 1 [54]
Rituximab 41 9 6 n.r. [55]
Subtotal 104 22 11 3
Anti-CD20 34 9 n.r. 2 [56]
Total 435 81 23 7
Number of people that have been infected with the COVID-19 virus that have been documented in case reports and registries from published and 
social media reports. It is not possible to exclude that people reported in case reports, registries and pharmacovigilance studies are repeat reporting. In 
addition, infection was defined by symptoms and was not always confirmed via viral nucleic acid testing or serology. n.r. = not reported.
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Infection of SARS-CoV-2 infection induces immunity
Although there is much hope for the impact of vaccina-
tion on generating immunity to SARS-CoV-2, there is no 
guarantee of protection or prolonged protection [24,80]. 
Repeated infection is observed with other endemic human 
coronaviruses that cause common colds, suggesting that 
recurrent reinfections may also occur with SARS-CoV-2 
[81]. This strongly supports the contribution of mac-
rophages in viral control and the limited and transient 
induction of adaptive immunity [81]. Possible reinfection 
with SARS-Cov-2 has also been suggested by the finding 
of positive, polymerase chain reaction (PCR)-detected 
SARS-CoV-2 nucleic acid swabs after a number of nega-
tive swabs [82]. However, it is clear that this may be due 
to non-infective viral particles or artefacts created by 
sampling location and the testing systems used. PCR-
positive swabs can be found in faeces long after loss of 
nasopharyngeal-positive PCR findings, indicating that the 
virus may persist for some time and that the PCR test 
detects fragments of the viral nucleic acid and not neces-
sarily infective virus [83,84]. Importantly, contact tracing 
of hundreds of people with positive tests after previous 
negative tests and hospital discharge failed to detect any 
evidence of the production of infective virus and subse-
quent viral spread to contacts [84]. Importantly, animal 
model studies show that immunity to SARS-COV-2 devel-
ops after primary infection that can rapidly eliminate the 
virus on re-exposure [28,29,85]. This can be stimulated 
via vaccination in animals and in humans to generate 
neutralizing antibodies [86,87]. In most, but not all cases, 
neutralizing antibodies persist for a number of months 
[79,80], and following SARS coronavirus infection SARS-
CoV-specific antibodies were detectable for a year or two 
before they disappeared [88], due probably to lack of 
antigenic stimulation following elimination of the virus. 
However, as new responses will be generated from CD20+ 
naive B cells, these responses would be anticipated to be 
blunted by B cell depleting agents.
CD20 antibodies inhibit vaccine responses
It has been shown that rituximab depletes naive B cells 
in the blood, lymphoid tissue and, to some extent, the 
bone marrow, and can also disrupt germinal centre for-
mation in secondary lymphoid tissues [3,89,90]. Although 
the influence of ocrelizumab on B cell subsets and vaccine 
responses have not been published, trial (NCT02545868) 
data have been reported in meetings and adopted in the 
Summary of Product Characteristics produced as part of 
the regulatory label [67,91]. Importantly, the data have 
been deposited on a trial registration site (www.clini caltr 
ials.gov) allowing data extraction, as shown here (Fig. 2). 
It is evident that there is a lower frequency of 
seroconversion and reduced titre to 23-valent pneumococ-
cal polysaccharide vaccine (23-PPV) (Fig. 2a,b) with or 
without a booster vaccine (Fig. 2c), keyhole limpet haemo-
cyanin (KLH) neoantigen (Fig. 2d), tetanus toxoid vaccine 
(Fig. 2e,f) and seasonal influenza vaccines (Fig. 2g–i). The 
percentage of people with MS who gave a positive response 
(titre  ≥ 0·2  IU/ml or fourfold increase in titre is baseline 
levels  ≥ 0·1  IU) to tetanus vaccine 8 weeks after vaccina-
tion was 23·9% in the ocrelizumab group compared to 
54·5% in the control group (no DMT except interferon 
beta). The geometric mean anti-tetanus toxoid-specific 
antibody titres at 8 weeks were 3·74 and 9·81  IU/ml, 
respectively. Although these vaccine booster responses to 
tetanus toxoid were clearly blunted (Fig. 2c), the titres 
were generally above protective levels (0·16  IU/ml) [92], 
even at baseline. The percentage of people with MS on 
ocrelizumab with seroprotective titres against five influenza 
strains ranged from 20·0−60·0 and 16·7−43·8% prevaccina-
tion, and at 4 weeks post-vaccination from 55·6−80·0%, 
in people treated with ocrelizumab and 75·0−97·0% in 
the control group, respectively (Fig. 2g). However, haemag-
gulination inhibition titres were reduced (Fig. 2h). Similarly, 
while there was a positive response to five or more sero-
types in polyvalent pneumococcal vaccine (23-PPV) at 4 
weeks after vaccination (71·6% in the ocrelizumab group 
and 100% in the control group), the frequency of sero-
conversion and antibody titres were, however, markedly 
reduced (Fig. 2a). Furthermore, a booster of the 13-PPV 
vaccine administered 4  weeks later did not markedly 
enhance the response to 12 serotypes, in common with 
23-PPV (Fig. 2c), further indicating the blunting of the 
vaccine responses. This was also seen using KLH (Fig. 
2d). It is likely that this would be reduced further fol-
lowing repeated infusion of ocrelizumab, as hypogamma-
globulinaemia, notably within IgM production, develops 
and increases while IgG hypogammaglobulinaemia develops 
over a longer time-frame [9,15].
The relatively poor vaccine response in people treated 
with ocrelizumab was predictable, and consistent with that 
seen following vaccination in people treated with rituximab, 
suggesting that this is an issue for all classes of anti-CD20 
antibodies used in the treatment of cancer and autoim-
mune diseases. There was a reduced titre and seroconver-
sion rate (37·5 versus 75·0% healthy controls) of people 
with NMOSD following vaccination against influenza 
(H1N1) virus 3–5  weeks after treatment with rituximab 
[93]. Furthermore, vaccine responses to Streptococcus pneu-
moniae and influenza were still impaired in people with 
idiopathic thrombocytopenia and RA 6 months after treat-
ment [94,95]. This conclusion was also supported by studies 
in RA following treatment with rituximab, with a more 
markedly blunted seroconversion and titre when vaccinated 
during periods of peripheral B cell depletion with influenza 
D. Baker et al.
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[96], hepatitis B vaccines [97], PPV-23, KLH [94] and a 
greater, but still blunted, vaccine response 6–10  months 
after infusion [96]. However, despite a relative lack of 
memory B cells, CD19-repopulated individuals could mount 
a robust recall response, as shown in people with 
pemphigus vulgaris [98]. This suggests that it is possible 
to create a time-window to vaccinate an individual due 
to the differential kinetics of repopulation with pathogenic 
memory B cells and naive B cells that will allow immunity 
to new infections [3,99,100]. In addition, ocrelizumab does 
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not appear to impair pre-existing humoral immunity [101], 
suggesting that people with MS who receive the SARS-
CoV-2 vaccine if and when it becomes available will be 
able to start treatment with ocrelizumab without risking 
vaccine-acquired immunity. However, the effect of ocre-
lizumab-induced hypogammaglobulinaemia on the levels 
of protection from prior immunizations is unknown, and 
warrants further investigation.
Repopulation kinetics of ocrelizumab
If COVID-19-related vaccine responses become a key 
concern among people with MS or other autoimmune 
diseases choosing treatment options, the selection of B 
cell-depleting agents that allow quick repopulation of B 
cells may be relevant for optimum vaccine readiness. 
Continuous B cell depletion with ocrelizumab and rituxi-
mab will clearly limit naive B cell repopulation; however, 
memory B cell depletion persists for a significant time 
after depletion with rituximab and alemtuzumab, consistent 
with the slow repopulation of this subset [99,100,102,103]. 
This suggests a possibility for extended interval dosing 
or dosing interruption to allow immature B cells to recover 
to facilitate vaccination, while maintaining low levels of 
pathogenic memory B cells. Data suggest that this is fea-
sible, at least with rituximab [98]. The timing required 
for this to occur for ocrelizumab is likely to be substan-
tially longer. Repletion with rituximab occurs within 
approximately 6  months of treatment, and is completed 
within 12  months due to repopulation of the immature/
mature (naive) B cell pool [26,98]. Monthly subcutaneous 
treatment with ofatumumab takes a median of 49  weeks 
(range  =  14–102 weeks) for CD19 B cell repletion after 
six 60-mg cycles of treatment, and immature (CD19+, 
CD38+, CD10+) cells repopulate quickly [104]. This may 
have some merits for ofatumumab if the rapid repopula-
tion of B cells can be confirmed with more prolonged 
usage, once ofatumumab is licenced to treat MS. 
Repopulation of B cell subsets following ocrelizumab has 
not been reported previously, but we report here the influ-
ence of ocrelizumab on B cell subsets from the Phase II 
open-label extension study (Fig. 3a,b) [105]. It was found 
that CD4 and CD8 T cell numbers were relatively unaf-
fected (Fig. 3a,b), even during active treatment (Fig. 3b). 
CD19 B cell subsets, including memory (CD19+, CD27+, 
CD38low) B cells, are completely depleted during active 
treatment (Fig. 3b). Even following cessation of treatment, 
CD19+ B cells remain low for 6–12  months after the last 
infusion (Fig. 3a). It is evident, however, that the memory 
B cell pool remained depleted for much longer, at least 
18  months (Fig. 3a,b), and probably even longer in many 
individuals [105]. This is consistent with the durability of 
relapse inhibition and adds further support to the view 
that cells within this subset are important in MS disease 
pathogenesis [2,9]. However, there appeared to be some 
recovery of the naive (CD19+, CD21, IgD+, IgM+) B cell 
pool during this time (Fig. 3a), suggesting the potential 
to generate new antibody responses which may be crucial 
to mount an immune response during infections and vac-
cinations. As found with rituximab, naive/mature B cell 
repopulation will coincide with CD19 repopulation [26,97] 
and would take a median 62–72  weeks after three [95% 
confidence interval (CI)  =  59·7–73·0  weeks, n  =  51] or 
four cycles (95% CI  =  59·1–85·4, range  =  27–175 weeks, 
n  =  51), respectively [105]. Such levels would require 
monitoring, as there is marked variability in repopulation 
kinetics between individuals and is, in part, a product of 
the ocrelizumab fixed-dosing schedule, as it is clear that 
the intensity of B cell depletion and repopulation speed 
relates to the body mass index of the individual [106,107]. 
This suggests that dose-adjustment for weight may have 
some benefit, as currently used in the treatment of people 
with MS with oral cladribine [107]. Cladribine can be 
Fig. 2. Ocrelizumab inhibits vaccination responses. People with multiple sclerosis who did not receive ocrelizumab (control) or were infused with 
300 mg ocrelizumab on days 0 and 15 and were vaccinated from weeks 12–24 after ocrelizumab. The experimental details and results were from www.
clini caltr ials.gov NCT02545868 [91]. The results show: (a) The frequency of seroconversion in people treated with ocrelizumab following injection 
pneumococcal 23-polyvalent pneumococcal vaccine (PPV) vaccine, 4 weeks after vaccination (n = 66–68). A 23-PPV vaccine response against a 
serotype was defined by a twofold increase in anti-pneumococcal antibody or > 1 µg/ml compared with prevaccination levels, following Food and 
Drug Administration guidance. (b) The titre of response to the initial challenge with 23-PPV 4 weeks after vaccination. (c) The frequency of 
seroconversion in people treated with ocrelizumab following injection of a booster pneumococcal 13-PPV vaccine 4 weeks after 23-PPV (n = 33–34). 
The frequency of responders is shown 8 weeks after 23-PPV vaccination. (d) The geometric mean and 95% confidence interval (CI) anti-tetanus 
toxoid antibody levels measured by enzyme-linked immunosorbent assay (ELISA) before and following vaccination (n = 34–68). (e,f) The geometric 
mean and 95% confidence interval titre of (e) immunoglobulin (Ig)M or (f) IgG keyhole limpet haemocyanin (KLH)-specific antibody after 
vaccination with keyhole limpet haemocyanin at baseline, weeks 4 and 8 started 12 weeks after ocrelizumab infusion (n = 34–68). (g–i) The response 
to: A/California/7/2009 (H1N1, n = 33–35); B/Phuket/3073/2013 (BPH, n = 31–33), A/Switzerland/9715293/2013 (H3N2, n = 27–30), B/
Brisbane/60/2008 (BBR, n = 16–18), A/Hong Kong/4801/2014 (AHK, n = 5–6) influenza strain vaccination 12 weeks after ocrelizumab infusion was 
assessed. The results represent (g) the percentage of people with seroconversion, defined either a prevaccination haemagglutination inhibition (HI) 
titre < 10 and ≥ 40 at 4 weeks or a prevaccination ≥ 10 and at least a fourfold increase in HI titre, and seroprotection defined by titres > 40 at 4 weeks 
after vaccination. (h) The change in the geometric mean HI titres before and after vaccination (I) The percentage of people with a fourfold increase in 
strain-specific > 40) at 4 weeks after vaccination.
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considered to be a chemical CD19-depleting agent that 
markedly depletes memory B cells while generally main-
taining T cells within the lower limit of normal. The 
compound is rapidly eliminated, allowing CD19 naive B 
cells to recover within a median of 30  weeks after treat-
ment [108–110]. Alemtuzumab is administered at a low 
dose (36–60  mg) per cycle compared to ocrelizumab 
(600  mg) and rituximab (500–1000  mg), and has a rela-
tively short half-life compared to ocrelizumab [111]. 
Alemtuzumab markedly depletes T cells and memory B 
cells, but naive B cells rapidly repopulate [100,103], and 
vaccine-related antibody responses can be induced within 
6  months of infusion [112]. This further supports the 
concept of a ‘window for vaccination’ for CD20-depleting 
antibodies.
However, while B cell responses to a variety of different 
vaccines are clearly inhibited by CD20 depletion despite 
some inhibition of CD20 T cells [99,113], inactivated 
herpes zoster vaccine can at least induce T cell responses 
[114]. This may be relevant if the CD8 T cell response 
is a vital part of the coronavirus specific immunity, as 
reported for SARS-CoV [27,115–118]. This feature may 
reduce concern about the limited antibody responses that 
may be generated following infection or after administra-
tion of a SARS-CoV-2 vaccine, as such asymptomatic 
people who have cleared SARS-CoV-2 and have a detect-
able anti-viral T cell response, but may not generate an 
antibody response [115–118]. Although adenoviral vaccines 
have shown some value in generating neutralizing anti-
bodies and cytopathic T cells in early human studies [85], 
live and attenuated viruses are contraindicated in immu-
nosuppressed people [67]. It remains to be seen if SARS-
CoV-2 DNA-RNA vaccines [24], will be useful in people 
taking immunosuppressive agents. However, it is important 
that people with autoimmunity continue to be offered the 
benefit that high-efficacy immunotherapy can provide. With 
time, further knowledge will emerge that may help guide 
treatment selection within the COVID-19 and post-
COVID-19 era.
Acknowledgements
This study received no funding. The authors thank Roche 
and ClinicalStudyDataRequest.com for providing access to 
the clinical trial data. We thank Alison Schroeer (Schroeer 
Scientific Illustration) for advice and assistance concerning 
figure production and Dr Roger D. Seheult, (MedCram) 
for invaluable insights relating to pulmonary medicine and 
COVID-19.
Disclosures
D. B., M. M., K. S. and G. G. have received compensation 
for either consultancies and presentations and advisory 
board activities from Genentech/Roche. However, Roche/
Genentech were not involved in the decision to write and 
submit this manuscript. S. A. has received consultancy 
from Novartis and Roche. C. A. K. K., G. P., A. S. K. and 
S. R. have nothing to disclose. D. B. has received 
Fig. 3. Long-term depletion of memory B cells induced by ocrelizumab. These data were extracted from the ocrelizumab Phase II clinical study report 
[105], supplied by the trial sponsor via the www.clini caltr ialda tareq uest.com portal. (a) The data represents the mean percentage change from baseline, 
defined as the last observation up to the first day of ocrelizumab treatment. The subjects received placebo and three cycles of 600 mg ocrelizumab 
every 24 weeks. This was followed by a treatment-free period to monitor B cell repletion in the Phase II extension study. The time represents the 
period from the last ocrelizumab infusion (n = 22–43). Naive [CD19+, CD21+, immunoglobulin (IgD)+, IgM+] and memory B cells (CD19+, CD27+, 
CD38low) and other immune subsets were assessed (n = 22–43/group). (b) Depletion of memory B cells was maintained during treatment. These data 
were obtained from people (n = 88) entering the open-label extension (OLE) study after the treatment-free period that had received three or four 
6-monthly cycles of at least 600 mg ocrelizumab to week 72, followed by a treatment-free period to week 144, before entering the OLE phase where 
600-mg cycles of ocrelizumab were maintained at 24-week intervals. The results represent the mean ± standard deviation of cells/μl (n = 22–69/group 
weeks 22–72). Although CD19 B cell numbers were consistent with the original levels, the baseline memory B cell levels failed to return to original 
levels at the start of the OLE. PMN = polymorphonuclear neutrophil.
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
© 2020 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society 
for Immunology, Clinical and Experimental Immunology, 0: 9–13
9
compensation for activities related to Canbex therapeutics, 
InMune Biol, Lundbeck, Japan tobacco, Merck and Novartis. 
M. M. has received speaking honoraria from Sanofi-
Genzyme. K. S. has received compensation for activities 
related to Biogen, Eisai, Elan, Fiveprime, Lipomed, Merck 
KGAa, Novartis, Sanofi-Genzyme and Teva. G. G. has 
received compensation for activities from AbbVie, Actelion, 
Atara Bio, Bayer-Schering Healthcare, Biogen, Celgene, GW 
Pharma, GSK, Ironwood, Japanese Tobacco, Merck, Merck-
Serono, Mertz, Novartis, Pfizer, Sanofi-Genzyme, Synthon, 
Takeda, Teva, UCB Pharma and Vertex Pharmaceuticals.
References
 1 Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 
monoclonal antibodies in autoimmune disease treatment. Auto 
Immun Highlights 2017; 8:12.
 2 Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. 
Memory B-cells are major targets for effective immunotherapy 
in relapsing multiple sclerosis. EBioMedicine 2017; 
16:41–50.
 3 Baker D, Pryce G, Amor S, Giovannoni G, Schmierer K. Learning 
from other autoimmunities to understand targeting of B-cells 
to control multiple sclerosis. Brain 2018; 141:2824–8.
 4 Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal 
antibodies for lymphoma therapy. J Hematol Oncol 2012; 5:64.
 5 Sabatino JJ, Zamvil SS, Hauser SL. B-cell therapies in multiple 
sclerosis. Cold Spring Harb Perspect Med 2019; 9:a032037.
 6 Hauser SL, Bar-Or A, Cohen J et al. Efficacy and safety of 
ofatumumab versus teriflunomide in relapsing multiple sclerosis: 
results of the phase 3 ASCLEPIOS I and II trials. Mult Scler 
2019; 25(Suppl 2):890–1.
 7 Fox E, Lovett-Racke AE, Gormley M et al. A phase 2 multicenter 
study of ublituximab, a novel glycoengineered anti-CD20 
monoclonal antibody, in patients with relapsing forms of 
multiple sclerosis. Mult Scler 2020. https://doi.org/10.1177/ 
13524 58520 918375.
 8 Ineichen BV, Moridi T, Granberg T, Piehl F. Rituximab treatment 
for multiple sclerosis. Mult Scler 2020; 26:137–52.
 9 Baker D, Pryce G, James LK, Marta M, Schmierer K. The 
ocrelizumab phase II extension trial suggests the potential to 
improve the risk:benefit balance in multiple sclerosis. Mult Scler 
Relat Disord 2020. https://doi.org/10.1101/2020.01.09.20016774.
 10 Juto A, Fink K, Nimer F, Piehl F. Interrupting rituximab 
treatment in relapsing–remitting multiple sclerosis; no evidence 
of rebound disease activity. Mult Scler Relat Disord 2020; 
37:101468.
 11 Trouvin AP, Jacquot S, Grigioni S et al. Usefulness of monitoring 
of B-cell depletion in rituximab-treated rheumatoid arthritis 
patients in order to predict clinical relapse: a prospective 
observational study. Clin Exp Immunol 2015; 180:11–8.
 12 Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Repeated treatment 
with rituximab based on the assessment of peripheral circulating 
memory B-cells in patients with relapsing neuromyelitis optica 
over 2 years. Arch Neurol 2011; 68:1412–20.
 13 Novi G, Fabbri S, Bovis F et al. Tailoring B-cells depleting 
therapy in MS according to memory B-cells monitoring: a 
pilot study. P971. Mult Scler 2019; 25(Suppl 2):509–10.
 14 Marcinnò A, Marnetto F, Valentino P et al. Rituximab-induced 
hypogammaglobulinemia in patients with neuromyelitis optica 
spectrum disorders. Neurol Neuroimmunol Neuroinflamm 
2018; 5:e498.
 15 Derfuss T, Weber MS, Hughes R et al. Serum immunoglobulin 
levels and risk of serious infections in the pivotal Phase III 
trials of ocrelizumab in multiple sclerosis and their open-label 
extensions. 65. Mult Scler 2019; 25(Suppl 2):20–1.
 16 Luna G, Alping P, Burman J et al. Infection risks among 
patients with multiple sclerosis treated with fingolimod, 
natalizumab, rituximab, and injectable therapies. JAMA Neurol 
2019; 77:184.
 17 Baloch S, Baloch MA, Zheng T, Pei X. The coronavirus disease 
2019 (COVID-19) pandemic. Tohoku J Exp Med 2020; 
250:271–8.
 18 Huang C, Wang Y, Li X et al. Clinical features of patients 
infected with 2019 novel coronavirus in Wuhan, China 
[published correction appears in Lancet 2020 30 January]. 
Lancet 2020; 395:497–506.
 19 Brownlee W, Bourdette D, Broadley S, Killestein J, Ciccarelli 
O. Treating multiple sclerosis and neuromyelitis optica spectrum 
disorder during the COVID-19 pandemic. Neurology 2020; 
94:949–52.
 20 Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G. The 
underpinning biology relating to multiple sclerosis disease 
modifying treatments during the COVID-19 pandemic. Mult 
Scler Relat Disord 2020; 43:102174.
 21 Xu X, Chang XN, Pan HX et al. Pathological changes of the 
spleen in ten patients with coronavirus disease 2019 
(COVID-19) by postmortem needle autopsy. Zhonghua Bing 
Li Xue Za Zhi 2020; 49:576–82.
 22 Henry BM, Vikse J, Benoit S, Favaloro EJ, Lippi G. 
Hyperinflammation and derangement of renin-angiotensin-
aldosterone system in COVID-19: A novel hypothesis for 
clinically suspected hypercoagulopathy and microvascular 
immunothrombosis. Clin Chim Acta 2020; 507:167–73.
 23 AminJafari A, Ghasemi S. The possible of immunotherapy for 
COVID-19: a systematic review. Int Immunopharmacol 2020; 
83:106455.
 24 Le Thanh T, Andreadakis Z, Kumar A et al. The COVID-19 
vaccine development landscape. Nat Rev Drug Discov 2020; 
19:305–6.
 25 Randolph HE, Barreiro LB. Herd immunity: understanding 
COVID-19. Immunity 2020; 52:737–41.
 26 Bar-Or A, Calabresi PA, Arnold D et al. Rituximab in relapsing–
remitting multiple sclerosis: a 72-week, open-label, phase I 
trial. Ann Neurol 2008;63:395–400.
D. Baker et al.
© 2020 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for 
Immunology, Clinical and Experimental Immunology, 0: 10–13
10
 27 Channappanavar R, Fett C, Zhao J, Meyerholz DK, Perlman 
S. Virus-specific memory CD8 T-cells provide substantial 
protection from lethal severe acute respiratory syndrome 
coronavirus infection. J Virol 2014; 88:11034–44.
 28 Bao L, Deng W, Gao H et al. Reinfection could not occur 
in SARS-CoV-2 infected rhesus macaques. bioRxiv 2020. https://
doi.org/10.1101/2020.03.13.990226.
 29 Bao L, Deng W, Huang B et al. The pathogenicity of SARS-
CoV-2 in hACE2 transgenic mice. Nature 2020. https://doi.
org/10.1038/s4158 6-020-2312-y.
 30 Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant 
E, Gold J. The COVID-19 pandemic and the use of MS 
disease-modifying therapies. Mult Scler Relat Disord 2020; 
39:102073.
 31 Berger JR, Brandstadter R, Bar-Or A. COVID-19 and MS 
disease-modifying therapies. Neurol Neuroimmunol 
Neuroinflamm 2020; 7:e761.
 32 Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, 
Caporali R. COVID-19 infection and rheumatoid arthritis: 
faraway, so close! Autoimmun Rev 2020; 19:102523.
 33 Wang B, Wang L, Kong X et al. Long term coexistence of 
SARS-CoV-2 with antibody response in COVID-19 patients. 
J Med Virol 2020. https://doi.org/10.1002/jmv.25946.
 34 Anand P, Slama MCC, Kaku M et al. COVID-19 in patients 
with myasthenia gravis. Muscle Nerve 2020. https://doi.
org/10.1002/mus.26918.
 35 Dworakowska D, Grossman AB. Thyroid disease in the time 
of COVID-19. Endocrine 2020; 68:471–4. https://doi.
org/10.1007/s1202 0-020-02364 -8.
 36 Salvarani C, Bajocchi G, Mancuso P et al. Susceptibility and 
severity of COVID-19 in patients treated with bDMARDS 
and tsDMARDs: a population-based study. Ann Rheum Dis 
2020. https://doi.org/10.1136/annrh eumdi s-2020-217903.
 37 Novi G, Mikulska M, Briano F et al. COVID-19 in a MS 
patient treated with ocrelizumab: does immunosuppression 
have a protective role? Mult Scler Relat Disord 2020; 
15:102120.
 38 Louapre C, Maillart E, Roux T et al. Patients with MS treated 
with immunosuppressive agents: across the COVID-19 
spectrum. Rev Neurol 2020; 176:523–5.
 39 Montero-Escribano P, Matías-Guiu J, Gómez-Iglesias P, Porta-
Etessam J, Pytel V, Matias-Guiu JA. Anti-CD20 and COVID-19 
in multiple sclerosis and related disorders: a case series of 
60 patients from Madrid, Spain. Mult Scler Relat Disord 2020; 
42:102185.
 40 Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies 
may affect susceptibility to acute respiratory illness among 
patients with multiple sclerosis during the early COVID-19 
epidemic in Iran. Mult Scler Relat Disord 2020; 43:102195.
 41 Hughes R, Pedotti R, Koendgen H. COVID-19 in persons with 
multiple sclerosis treated with ocrelizumab – a pharmacovigilance 
case series. Mult Scler Relat Disord 2020; 42:102192.
 42 Suwanwongse K, Shabarek N. Benign course of COVID-19 
in a multiple sclerosis patient treated with ocrelizumab. Mult 
Scler Relat Disord 2020; 42:102201.
 43 Ghajarzadeh M, Mirmosayyeb O, Barzegar M et al. Favorable 
outcome after COVID-19 infection in a multiple sclerosis 
patient initiated on ocrelizumab during the pandemic. Mult 
Scler Relat Disord 2020; 43:102222.
 44 Chaudhry F, Bulka H, Rathnam AS et al. COVID-19 in multiple 
sclerosis patients and risk factors for severe infection. medRxiv 
2020. https://doi.org/10.1101/2020.05.27.20114827.
 45 Sormani MP; Italian Study Group on COVID-19 Infection in 
Multiple Sclerosis. An Italian programme for COVID-19 
infection in multiple sclerosis. Lancet Neurol 2020; 
19:481–2.
 46 Salter A. iWiMS MS Covid-19. 13 May 2020 (https://youtu.
be/XAiBJ 2sphkU).
 47 Assmuth Oreja CS.iWiMS MS Covid-19. 6 May 2020. Available 
at: https://youtu.be/cp0rt xq_k2Y.
 48 van der Welt A, Health A.iWiMS MS Covid-19. 6 May 2020. 
Available at: https://youtu.be/cp0rt xq_k2Y.
 49 Louapre C, Collongues N, Stankoff B et al. Clinical 
characteristics and outcomes in patients with coronavirus 
disease 2019 and multiple sclerosis. JAMA Neurol 2020. https://
doi.org/10.1001/jaman eurol.2020.2581.
 50 Meca-Lallana V, Aguirre C, del Río B, Cardeñoso L, Alarcon 
T, Vivancos J. COVID-19 in 7 multiple sclerosis patients in 
treatment with anti CD20 therapies. Mult Scler Relat Disord 
2020; 44:102306. accessed 20 May 2020.
 51 Conte WL. Attenuation of antibody response to SARS-CoV-2 
in a patient on ocrelizumab with hypogammaglobulinemia. 
Mult Scler Relat Disord 2020; 44:102315.
 52 Rempe Thornton J, Harel A. Negative SARS-CoV-2 antibody 
testing following COVID-19 infection in two MS patients 
treated with ocrelizumab. Mult Scler Rel Disord 2020. https://
doi.org/10.1016/j.msard.2020.102341.
 53 Lucchini M, Bianco A, Del Giacomo P, De Fino C, Nociti V, 
Mirabella M. Is serological response to SARS-CoV-2 preserved 
in MS patients on ocrelizumab treatment? A case report. Mult 
Scler Relat Disord 2020. https://doi.org/10.1016/j.
msard.2020.102323.
 54 Barzegar M, Mirmosayyeb O, Ghajarzadeh M et al. 
Characteristics of COVID-19 disease in multiple sclerosis 
patients. Mult Scler Relat Disord 2020; 45:102276. 
 55 Hillert J. iWiMS MS Covid-19. 20 May 2020. Available at: 
https://youtu.be/z4sRB QEv0yE.
 56 Parrotta E, Kister I, Charvet L et al. COVID-19 outcomes in 
MS: early experience from NYU multiple sclerosis 
comprehensive care center. medRxiv 2020. https://doi.org/10.
1101/2020.05.12.20094508.
 57 Suthar MS, Zimmerman M, Kauffman R et al. Rapid generation 
of neutralizing antibody responses in COVID-19 patients. 
medRxiv 2020. https://doi.org/10.1101/2020.05.03.20084442.
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
© 2020 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society 
for Immunology, Clinical and Experimental Immunology, 0: 11–13
11
 58 Bertoglio F, Meier D, Langreder N et al. SARS-CoV-2 
neutralizing human recombinant antibodies selected from pre-
pandemic healthy donors binding at RBD–ACE2 interface. 
bioRxiv 2020. https://doi.org/10.1101/2020.06.05.135921.
 59 Zeng QL, Yu ZJ, Gou JJ et al. Effect of convalescent plasma 
therapy on viral shedding and survival in COVID-19 patients. 
J Infect Dis 2020:jiaa228.
 60 Ye M, Fu D, Ren Y et al. Treatment with convalescent plasma 
for COVID-19 patients in Wuhan, China. J Med Virol 2020. 
https://doi.org/10.1002/jmv.25882.
 61 Soresina A, Moratto D, Chiarini M et al. Two X-linked 
agammaglobulinemia patients develop pneumonia as 
COVID-19 manifestation but recover. Pediatr Allergy Immunol 
2020. https://doi.org/10.1111/pai.13263.
 62 Quinti I, Lougaris V, Milito C et al. A possible role for B-cells 
in COVID-19? Lesson from patients with agammaglobulinemia. 
J Allergy Clin Immunol 2020; 146:211–3.e4.
 63 Ackermann M, Verleden SE, Kuehnel M et al. Pulmonary 
vascular endothelialitis, thrombosis, and angiogenesis in 
Covid-19. N Engl J Med 2020. https://doi.org/10.1056/NEJMo 
a2015432.
 64 Tseng YH, Yang RC, Lu TS. Two hits to the renin–angiotensin 
system may play a key role in severe COVID-19. Kaohsiung 
J Med Sci 2020. https://doi.org/10.1002/kjm2.12237.
 65 Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VERSUS, 
Montecucco C. Clinical course of COVID-19 in a series of 
patients with chronic arthritis treated with immunosuppressive 
targeted therapies. Ann Rheum Dis 2020; 79:667–8.
 66 Gianfrancesco M, Hyrich KL, Al-Adely S et al. Characteristics 
associated with hospitalisation for COVID-19 in people with 
rheumatic disease: data from the COVID-19 Global 
Rheumatology Alliance physician-reported registry. Ann Rheum 
Dis 2020. https://doi.org/10.1136/annrh eumdi s-2020-217871.
 67 Ocrevus® European public assessment report. 7/01/2019 update. 
Summary of product characteristics. Available at: https://www.
ema.europa.eu/en/docum ents/produ ct-infor matio n/ocrev us-
epar-produ ct-infor mation_en.pdf accessed 5 January 2020.
 68 Fallet B, Kyburz D, Walker UA. Mild course of coronavirus 
disease 2019 and spontaneous severe acute respiratory syndrome 
coronavirus 2 clearance in a patient with depleted peripheral 
blood B-cells due to treatment with rituximab. Arthritis Rheum 
2020; 2020. https://doi.org/10.1002/art.41380.
 69 Xiang F, Wang X, He X et al. Antibody detection and dynamic 
characteristics in patients with COVID-19. Clin Infect Dis 
2020. https://doi.org/10.1093/cid/ciaa461.
 70 Shen L, Wang C, Zhao J et al. Delayed specific IgM antibody 
responses observed among COVID-19 patients with severe 
progression. Emerg Microbes Infect 2020; 9:1096–101.
 71 Yu HQ, Sun BQ, Fang ZF et al. Distinct features of SARS-
CoV-2-specific IgA response in COVID-19 patients. Eur Respir 
J 2020; 8:2001526.
 72 Dahlke C, Heidepriem J, Kobbe R et al. Distinct early IgA 
profile may determine severity of COVID-19 symptoms: an 
immunological case series. medRxiv 2020. https://doi.org/10.
1101/2020.04.14.20059733.
 73 Grifoni A, Weiskopf D, Ramirez SI et al. Targets of T cell 
responses to SARS-CoV-2 coronavirus in humans with 
COVID-19 disease and unexposed individuals. Cell 2020; 
181:1489–1501.e15.
 74 Ng K, Faulkner N, Cornish G et al. Pre-existing and de novo 
humoral immunity to SARS-CoV-2 in humans. bioRxiv 2020. 
https://doi.org/10.1101/2020.05.14.095414.
 75 Che XY, Qiu LW, Liao ZY et al. Antigenic cross-reactivity 
between severe acute respiratory syndrome-associated 
coronavirus and human coronaviruses 229E and OC43. J Infect 
Dis 2005; 191:2033–7.
 76 Negro F. Is antibody-dependent enhancement playing a role 
in COVID-19 pathogenesis? Swiss Med Wkly 2020; 150:w20249.
 77 Magro C, Mulvey JJ, Berlin D et al. Complement associated 
microvascular injury and thrombosis in the pathogenesis of 
severe COVID-19 infection: a report of five cases. Transl Res 
2020; 5244:1–13.
 78 Xiao T, Wang Y, Yuan J et al. Early viral clearance and antibody 
kinetics of COVID-19 among asymptomatic carriers. medRxiv 
2020. https://doi.org/10.1101/2020.04.28.20083139.
 79 Brochot E, Demey B, Touze A et al. Anti-spike, anti-nucleocapsid 
and neutralizing antibodies in SARS-CoV-2 inpatients and 
asymptomatic carriers. medRxiv 2020. https://doi.org/10.1101
/2020.05.12.20098236.
 80 Liu T, Wu S, Tao H et al. Prevalence of IgG antibodies to 
SARS-CoV-2 in Wuhan – implications for the ability to produce 
long-lasting protective antibodies against SARS-CoV-2. 
medRxiv 2020. https://doi.org/10.1101/2020.06.13.20130252.
 81 Galanti M, Shaman J. Seasonal cold-inducing coronavirus can 
be repeatedly detected in some individuals. medRxiv 2020. 
https://doi.org/10.1101/2020.04.27.20082032.
 82 Ravioli S, Ochsner H, Lindner G. Reactivation of COVID-19 
pneumonia: a report of two cases. J Infect 2020. https://doi.
org/10.1016/j.jinf.2020.05.008.
 83 Wang QX, Huang KC, Qi L, Zeng XH, Zheng SL. No infectious 
risk of COVID-19 patients with long-term fecal 2019-nCoV 
nucleic acid positive. Eur Rev Med Pharmacol Sci 2020; 
24:5772–7.
 84 Korean Centre for Disease Control and Prevention. Findings 
from investigation and analysis of re-positive cases. Notice 
2020–05-19~2020-12-31. accessed 19 May 2020. Available at: 
https/ is.cdc.gov.kr/upload_comm/syvie w/doc.html?fn=15911 
87458 23700.pdf&rs=/upload_comm/docu/0030.
 85 Chandrashekar A, Liu J, Martinot AJ et al. SARS-CoV-2 infection 
protects against rechallenge in rhesus macaques. Science 2020. 
https://doi.org/10.1126/scien ce.abc4776.
 86 Yu J, Tostanoski LH, Peter L et al. DNA vaccine protection 
against SARS-CoV-2 in rhesus macaques. Science 2020. https://
doi.org/10.1126/scien ce.abc6284.
 87 Zhu FC, Li YH, Guan XH et al. Safety, tolerability, and 
immunogenicity of a recombinant adenovirus type-5 vectored 
D. Baker et al.
© 2020 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for 
Immunology, Clinical and Experimental Immunology, 0: 12–13
12
COVID-19 vaccine: a dose-escalation, open-label, non-
randomised, first-in-human trial. Lancet 2020; 395:1845–54.
 88 Wu LP, Wang NC, Chang YH et al. Duration of antibody 
responses after severe acute respiratory syndrome. Emerg Infect 
Dis 2007; 13:1562–4.
 89 Cioc AM, Vanderwerf SM, Peterson BA, Robu VG, Forster 
CL, Pambuccian SE. Rituximab-induced changes in 
hematolymphoid tissues found at autopsy. Am J Clin Pathol 
2008; 130:604–12.
 90 Ramwadhdoebe TH, van Baarsen LGM, Boumans MJH et al. 
Effect of rituximab treatment on T and B-cell subsets in lymph 
node biopsies of patients with rheumatoid arthritis. 
Rheumatology 2019; 58:1075–85.
 91 Stokmaier D, Winthrop K, Chognot C et al. Effect of ocrelizumab 
on vaccine responses in patients with multiple sclerosis 
(S36.002). Neurology 2018; 90(15 Suppl):S36.002.
 92 Simonsen O, Bentzon MW, Heron I. ELISA for the routine 
determination of antitoxic immunity to tetanus. J Biol Standard 
1986; 14:231–9.
 93 Kim W, Kim SH, Huh SY et al. Reduced antibody formation 
after influenza vaccination in patients with neuromyelitis optica 
spectrum disorder treated with rituximab. Eur J Neurol 
2013;20:975–80.
 94 Bingham CO, Looney RJ, Deodhar A et al. Immunization 
responses in rheumatoid arthritis patients treated with 
rituximab: results from a controlled clinical trial. Arthritis 
Rheum 2010; 62:64–74.
 95 Nazi I, Kelton JG, Larché M et al. The effect of rituximab 
on vaccine responses in patients with immune thrombocyto-
penia. Blood 2013; 122:1946–53.
 96 van Assen S, Holvast A, Telgt DS et al. Patients with humoral 
primary immunodeficiency do not develop protective anti-
influenza antibody titers after vaccination with trivalent subunit 
influenza vaccine. Clin Immunol 2010; 136:228–35.
 97 Richi P, Alonso O, Martín MD et al. Evaluation of the immune 
response to hepatitis B vaccine in patients on biological therapy: 
results of the RIER cohort study. Clin Rheumatol 2020. https://
doi.org/10.1007/s1006 7-020-05042 -2.
 98 Cho A, Bradley B, Kauffman R et al. Robust memory responses 
against influenza vaccination in pemphigus patients previously 
treated with rituximab. JCI Insight 2017; 2:e93222.
 99 Palanichamy A, Jahn S, Nickles D et al. Rituximab efficiently 
depletes increased CD20-expressing T-cells in multiple sclerosis 
patients. J Immunol 2014; 193:580–6.
 100 Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, 
Schmierer K. Interpreting lymphocyte reconstitution data from 
the pivotal phase 3 trials of alemtuzumab. JAMA Neurol 2017; 
74:961–9.
 101 Ziemssen T, Bar-Or A, Arnold DL et al. P 2 Effect of ocrelizumab 
on humoral immunity markers in the phase iii, double-blind, 
double-dummy, IFN β -1a–controlled OPERA I and OPERA 
II studies. Clin Neurophysiol 2017; 128:e326–e327.
 102 Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. 
Regeneration of B-cell subsets after transient B-cell depletion 
using anti-CD20 antibodies in rheumatoid arthritis. Arthritis 
Rheum 2006; 54:2377–86.
 103 Akgün K, Blankenburg J, Marggraf M, Haase R, Ziemssen T. 
Event-driven immunoprofiling predicts return of disease activity 
in alemtuzumab-treated multiple sclerosis. Front Immunol 2020; 
11:56.
 104 Bar-Or A, Grove RA, Austin DJ et al. Subcutaneous ofatumumab 
in patients with relapsing-remitting multiple sclerosis: the 
MIRROR study. Neurology 2018; 90:e1805–e1814.
 105 WA21493 Clinical study report 2016. WA21493-Phase II, 
multicenter, randomized parallel-group, partially blinded, placebo, 
Avonex® controlled dose finding study to evaluate the efficacy 
as measured by brain MRI lesions and safety of 2 dose regimens 
of ocrelizumab in patients with RRMS. Report no. 1062910. 
March 2016. https://clini caltr ials.gov/ct2/show/NCT00 676715
 106 Signoriello E, Bonavita S, Di Pietro A et al. BMI influences 
CD20 kinetics in multiple sclerosis patients treated with 
ocrelizumab. Mult Scler Relat Disord 2020; 43:102186.
 107 Kletzl H, Gibiansky E, Petry C et al. Pharmacokinetics, 
pharmacodynamics and exposure-response analyses of 
ocrelizumab in patients with multiple sclerosis. Neurol 2019; 
92(Suppl 15):N4.001.
 108 Comi G, Cook S, Giovannoni G et al. Effect of cladribine 
tablets on lymphocyte reduction and repopulation dynamics 
in patients with relapsing multiple sclerosis. Mult Scler Relat 
Disord 2019; 29:168–74.
 109 Hermann R, Karlsson MO, Novakovic AM, Terranova N, Fluck 
M, Munafo A. The clinical pharmacology of cladribine tablets 
for the treatment of relapsing multiple sclerosis. Clin 
Pharmokinet 2019; 58:283–97.
 110 Baker D, Pryce G, Herrod SS, Schmierer K. Potential mechanisms 
of action related to the efficacy and safety of cladribine. Mult 
Scler Relat Disord 2019; 30:176–86.
 111 Li Z, Richards S, Surks HK, Jacobs A, Panzara MA. Clinical 
pharmacology of alemtuzumab, an anti-CD52 immunomo-
dulator, in multiple sclerosis. Clin Exp Immunol 2018; 194: 
295–314.
 112 McCarthy CL, Tuohy O, Compston DA, Kumararatne DS, 
Coles AJ, Jones JL. Immune competence after alemtuzumab 
treatment of multiple sclerosis. Neurology 2013; 81:872–6.
 113 Gingele S, Jacobus TL, Konen FF et al. Ocrelizumab depletes 
CD20⁺ T cells in multiple sclerosis patients. Cells 2018; 8:12.
 114 Parrino J, McNeil SA, Lawrence SJ et al. Safety and 
immunogenicity of inactivated varicella-zoster virus vaccine 
in adults with hematologic malignancies receiving treatment 
with anti-CD20 monoclonal antibodies. Vaccine 2017; 
35:1764–9.
 115 Ng OW, Chia A, Tan AT et al. Memory T-cell responses 
targeting the SARS coronavirus persist up to 11 years post-
infection. Vaccine 2016; 34:2008–14.
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
© 2020 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society 
for Immunology, Clinical and Experimental Immunology, 0: 13–13
13
 116 Robbiani DF, Gaebler C, Muecksch F et al. Convergent antibody 
responses to SARS-CoV-2 in convalescent individuals. Nature 
2020. https://doi.org/10.1038/s4158 6-020-2456-9.
 117 Gallais F, Velay A, Wendling MJ, Nazon C, Partisani M, Sibilia 
J, Candon S, Fafi-Kremer S. Intrafamilial exposure to SARS-
CoV-2 induces cellular immune response without 
seroconversion. medRxiv 2020. https://doi.org/10.1101/2020.0
6.21.20132449.
 118 Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T 
cell immunity in convalescent individuals with asymptomatic 
or mild COVID-19. bioRxiv 2020. https://doi.org/10.1101/2020. 
06.29.174888.
